The Global Hematologic Malignancies Market was valued at $42.8 Billion in 2017 and is forecast to grow at a modest XX.2 % CAGR between 2018 and 2025, culminating in 2025 global sales of $67.5 Billion.
There are no definitive causes for hematologic malignancies. These cells in hematologic cancers arise from types of white blood cells: lymphocytes, granulocytes, and plasma cells. Approximately one in every 3 minutes diagnosed with a blood cancer in U.S. 174,250 people in the US are expected to be diagnosed with leukemia, lymphoma or myeloma in 2018. New cases of leukemia, lymphoma, and myeloma are expected to account for 10 percent of the estimated 1,735,350 new cancer cases diagnosed in the US in 2018.
On an average every 9 minutes or 6 people every hour, in the US dies from a blood cancer. Leukemia, lymphoma, and myeloma are expected to cause the deaths of an estimated 58,100 people in the US in 2018. These account for 9.5 percent of the total deaths from cancer in 2018, based on the estimated total of 609,640 cancer deaths.
Check Out For Full Report Click Below Link
No comments:
Post a Comment